CSF2 and neuroblastoma: Fortunately, chemo-resistant NB is highly responsive to treatments far less toxic than myeloablative therapy, namely, anti-GD2 antibody + granulocyte–macrophage colony-stimulating factor (GM-CSF) [57] ± low-dose chemotherapy [58].